Endothelial progenitor cells: a new key for endothelial dysfunction in migraine
Xiana Rodríguez-Osorio1, Tomás Sobrino, David Brea
1Department of Neurology, Hospital Clínico Universitario, Universidad de Santiago de Compostela, Santiago de Compostela, Spain.
Neurology
|July 21, 2012
Summary
Migraine patients have fewer endothelial progenitor cells (EPCs) and higher levels of CGRP, NOx, and VEGF compared to controls. EPC numbers decline with longer migraine duration, indicating impaired endothelial function.
Area of Science:
- Neurology
- Cardiovascular Biology
- Cell Biology
Background:
- Endothelial dysfunction is implicated in various vascular conditions.
- Endothelial progenitor cells (EPCs) play a crucial role in vascular repair and maintenance.
- Migraine is a complex neurological disorder with potential vascular underpinnings.
Purpose of the Study:
- To investigate endothelial function in migraine patients using biochemical and ultrasonographic markers.
- To assess the relationship between endothelial function markers and endothelial progenitor cells (EPCs) in migraine.
Main Methods:
- A case-control study involving 47 episodic migraine patients and 23 controls.
- Analysis of flow-mediated dilation (FMD), calcitonin gene-related peptide (CGRP), vascular endothelial growth factor (VEGF), nitric oxide metabolites (NOx), and EPCs.
- Measurements were taken during interictal periods and migraine attacks.
Main Results:
- Migraine patients exhibited significantly lower EPC counts and higher levels of CGRP, VEGF, and NOx compared to controls.
- During migraine attacks, EPC numbers decreased, while CGRP and NOx levels increased.
- EPC counts were inversely correlated with the duration of migraine evolution.
Conclusions:
- Patients with migraine demonstrate impaired endothelial function, characterized by reduced EPCs and elevated CGRP, NOx, and VEGF.
- The progressive decline in EPCs with migraine duration suggests a link between disease progression and endothelial repair capacity.
- These findings highlight potential therapeutic targets for managing migraine-related vascular changes.


